Frontiers in endocrinology · 2026
Risk factors associated with aggressive tumor phenotypes in papillary thyroid microcarcinoma: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Orgoványi Máté, Rancz Anett, Dolhascu Anca, Agócs Gergely, Szentes Boglárka Lilla, Sipter Emese, Hegyi Péter, Kovács Gábor László
Аннотация
INTRODUCTION: In line with current guidelines, risk stratification in papillary thyroid microcarcinoma (PTMC) has shifted from simple diameter-based assessments to evaluation of individual tumor biology. Therefore, this study aimed to investigate how baseline clinical and molecular risk factors influence aggressive PTMC phenotypes.
METHODS: Registered in PROSPERO (CRD42024603662), we searched PubMed, Embase, and Cochrane through February 14, 2025. We analyzed risk factors for lymph node metastasis (LNM) and extrathyroidal extension (ETE) utilizing data from surgical cohorts of patients with PTMC, calculating pooled odds ratios (OR) and 95% confidence intervals (CI).
RESULTS: A total of 274 articles we found increased odds of central lymph node metastasis (CLNM) associated with male sex (OR = 1.86; CI:1.73-2.00), age (<45 and <55 years old OR = 1.61; CI:1.42-1.83 and OR = 1.89; CI:1.71-2.09), tumor size (>5 and >7 mm OR = 2.26; CI:2.00-2.56 and OR = 1.81; CI:1.11-2.96), multifocality (OR = 1.96; CI:1.78-2.16), bilaterality (OR = 1.70; CI:1.45-2.00) and BRAFV600E mutation (OR = 1.51; CI:1.25-1.82). Lateral lymph node metastasis (LLNM) was associated with male sex (OR = 1.69; CI:1.51-1.90), age (<45 and <55 years old OR = 1.5; CI:1.28-1.76 and CI:1.31-1.72), tumor size (>5 mm and >7 mm, OR = 2.34; CI:1.68-3.25 and OR = 3.71; CI:3.15-4.36), multifocality (OR = 1.98; CI:1.46-2.70) and bilaterality (OR = 1.91; CI:1.22-3.00). For ETE, risk factors were as follows: tumor size (>5 mm OR = 3.00; CI:2.03-4.45), multifocality (OR = 2.41; CI:1.99-2.91), bilaterality (OR = 2.58; CI:1.26-5.27), and BRAFV600E mutation (OR = 2.19; CI:1.61-2.97).
CONCLUSION: Male sex, age (<45 and <55 years), tumor size (>5 mm), multifocality, bilaterality, and BRAFV600E mutation are clinically relevant risk factors for aggressive PTMC phenotypes.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024603662, identifier CRD42024603662.
METHODS: Registered in PROSPERO (CRD42024603662), we searched PubMed, Embase, and Cochrane through February 14, 2025. We analyzed risk factors for lymph node metastasis (LNM) and extrathyroidal extension (ETE) utilizing data from surgical cohorts of patients with PTMC, calculating pooled odds ratios (OR) and 95% confidence intervals (CI).
RESULTS: A total of 274 articles we found increased odds of central lymph node metastasis (CLNM) associated with male sex (OR = 1.86; CI:1.73-2.00), age (<45 and <55 years old OR = 1.61; CI:1.42-1.83 and OR = 1.89; CI:1.71-2.09), tumor size (>5 and >7 mm OR = 2.26; CI:2.00-2.56 and OR = 1.81; CI:1.11-2.96), multifocality (OR = 1.96; CI:1.78-2.16), bilaterality (OR = 1.70; CI:1.45-2.00) and BRAFV600E mutation (OR = 1.51; CI:1.25-1.82). Lateral lymph node metastasis (LLNM) was associated with male sex (OR = 1.69; CI:1.51-1.90), age (<45 and <55 years old OR = 1.5; CI:1.28-1.76 and CI:1.31-1.72), tumor size (>5 mm and >7 mm, OR = 2.34; CI:1.68-3.25 and OR = 3.71; CI:3.15-4.36), multifocality (OR = 1.98; CI:1.46-2.70) and bilaterality (OR = 1.91; CI:1.22-3.00). For ETE, risk factors were as follows: tumor size (>5 mm OR = 3.00; CI:2.03-4.45), multifocality (OR = 2.41; CI:1.99-2.91), bilaterality (OR = 2.58; CI:1.26-5.27), and BRAFV600E mutation (OR = 2.19; CI:1.61-2.97).
CONCLUSION: Male sex, age (<45 and <55 years), tumor size (>5 mm), multifocality, bilaterality, and BRAFV600E mutation are clinically relevant risk factors for aggressive PTMC phenotypes.
SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024603662, identifier CRD42024603662.